InvestorsHub Logo
Followers 8
Posts 1893
Boards Moderated 0
Alias Born 05/05/2016

Re: Auto1 post# 17379

Thursday, 10/25/2018 10:30:37 AM

Thursday, October 25, 2018 10:30:37 AM

Post# of 44784

Seriously, zzaatt should be thanking us. Without our original thoughts in posts, it works have NOTHING to pay about or reply and quote...

I'm not sure what THAT means, but thanks anyway (LOL!). I'm especially grateful for the dozens of obsolete articles from years ago.

Shows the progress Pluristem has made, with P3 clinical trials, greater and greater understanding of the process of "training" (1) MSCs to specialize for specific indications, establishing partnerships to help in making PLX-PAD available in massive quantities, expanding an already rich patent portfolio, etc., ... all good!

1. training = induction, "Advancement of these therapies relies on the ability to direct MSCs toward specific cell phenotypes."

That's what Pluristem's scientists and academic collaborators have been doing for the last few years. That's how you get to radically new therapeutic modalities!